Related Experiment Videos
CD90 mediates gastric cancer immune evasion though regulating IGF2BP2 to stabilize the m6A-CD47/SIRPα axis
Siyi Liu1,2, Lin Liang1,2, Zihua Zhou3
1Department of Nuclear Medicine, The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University/Hunan Cancer Hospital & Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Abstract:
As a cell surface glycoprotein, CD90 plays a significant role in the initiation and progression of malignancies such as gastric cancer (GC) by influencing tumor cell proliferation, migration, and angiogenesis. However, its specific role in immune evasion in GC and its potential therapeutic value have not been fully explored. In this study, we report that CD90 is highly expressed in GC tissues and is positively correlated with macrophage immune infiltration. Furthermore, we demonstrate that CD90 can mediate immune evasion in GC by affecting the phagocytic function of tumor-associated macrophages (TAMs). Mechanistically, CD90 functions as a scaffold protein, inhibiting the interaction between IGF2BP2 and TRIM21. This inhibition stabilizes the expression of the m6A methylation reader protein IGF2BP2. Subsequently, IGF2BP2 enhances the mRNA stability of the immune checkpoint molecule CD47 in an m6A-dependent manner, leading to the activation of the CD47/SIRPα axis. Ultimately, by inhibiting the phagocytic function of TAMs, CD90 mediates immune evasion in GC. In summary, our work highlights the critical role of the CD90-IGF2BP2-CD47 axis in immune evasion in GC. This finding is expected to provide significant experimental evidence for elucidating the pathogenesis of GC and discovering potential molecular targets for clinical treatment.
Insights
CD90 promotes gastric cancer immune evasion by inhibiting macrophage phagocytosis via the IGF2BP2-CD47 axis. This study reveals CD90 as a potential therapeutic target for gastric cancer treatment.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- CD90 (Thy-1) is a cell surface glycoprotein implicated in cancer progression.
- Its role in gastric cancer (GC) immune evasion remains unclear.
- Understanding CD90's function is crucial for developing novel GC therapies.
Purpose of the Study:
- To investigate the role of CD90 in gastric cancer immune evasion.
- To elucidate the molecular mechanisms by which CD90 mediates immune evasion.
- To explore CD90 as a potential therapeutic target for GC.
Main Methods:
- Analysis of CD90 expression in GC tissues.
- Assessment of the correlation between CD90 and macrophage infiltration.
- Investigation of CD90's effect on tumor-associated macrophage (TAM) phagocytosis.
- Molecular experiments to determine the CD90-IGF2BP2-CD47 signaling pathway.
Main Results:
- CD90 is highly expressed in GC tissues and correlates with macrophage infiltration.
- CD90 inhibits TAM phagocytic function, thereby mediating immune evasion.
- CD90 acts as a scaffold, inhibiting IGF2BP2/TRIM21 interaction and stabilizing IGF2BP2.
- IGF2BP2 enhances CD47 mRNA stability in an m6A-dependent manner, activating the CD47/SIRPα axis.
Conclusions:
- The CD90-IGF2BP2-CD47 axis is critical for immune evasion in gastric cancer.
- CD90 plays a significant role in suppressing anti-tumor immunity by impairing TAM function.
- Targeting the CD90 pathway offers a promising strategy for GC immunotherapy.
Related Concept Videos
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Mitogens and the Cell Cycle
Gastritis II: Pathophysiology
Inhibition of Cdk Activity
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...